GNE-9815

CAS No. 2729996-45-4

GNE-9815( 3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide )

Catalog No. M28781 CAS No. 2729996-45-4

GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 222 Get Quote
10MG 357 Get Quote
25MG 597 Get Quote
50MG 851 Get Quote
100MG 1152 Get Quote
500MG 2313 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    GNE-9815
  • Note
    Research use only, not for human use.
  • Brief Description
    GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
  • Description
    GNE-9815 is a high kinase-selective inhibitor of RAF and targets KRAS-mutant cancers through combination therapy.
  • In Vitro
    GNE-9815 shows synergistic activity in KRAS mutant A549 and HCT116 cancer cells in combination with the MEK inhibitor Cobimetinib.
  • In Vivo
    GNE-9815 (15 mg/kg; p.o.; single) demonstrates synergistic MAPK pathway modulation when combines with the MEK inhibitor Cobimetinib in an HCT116 xenograft mouse model.GNE-9815 (5 mg/kg; p.o.; single) shows good oral bioavailability and (1 mg/kg; i.v.; single) exhibits low blood clearance, moderate volume of distribution, and short half-life. Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g; HCT116 xenograft mice model).Dosage:15 mg/kgAdministration:Intravenous injection or oral administration; single.Result:Resulted in pathway inhibition as demonstrated by partial inhibition of pRSK between 2 and 24 h, but more robust, albeit transient, inhibition of the downstream MAPK target genes, DUSP6 and SPRY4.Led to deeper inhibition of the downstream MAPK target genes DUSP6 and SPRY4, when combined with the MEK inhibitor Cobimetinib, with maximal inhibition at 8 h and with a more modest rebound in levels at 24 h, post final dose.Animal Model:Female NCR nude mice (6 to 8-week-old; 24-26 g).Dosage:1 mg/kg (for i.v.); 5 mg/kg (for p.o.).Administration:Intravenous injection or oral administration; single.Result:Exhibited CLb, Vdss and t1/2 values of 17 mL/min?kg, 1.7 L/kg and 1.9 h, respectively.Showed good oral bioavailability with F% of 37%. (methylcellulose/Tween formulation).
  • Synonyms
    3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide
  • Pathway
    MAPK/ERK Signaling
  • Target
    Raf
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2729996-45-4
  • Formula Weight
    455.48
  • Molecular Formula
    C26H22FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (109.77 mM)
  • SMILES
    N#CC(C=1C=CC=C(C1)C(=O)NC=2C=C(C3=CN=C4C(C=NN(C4=O)C)=C3)C(=CC2F)C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Gong J, et al. Salvianolic acid Y: a new protector of PC12 cells against hydrogen peroxide-induced injury from Salvia officinalis. Molecules. 2015 Jan 6;20(1):683-92.
molnova catalog
related products
  • Exarafenib

    Exarafenib (RAF/KIN_2787) is a potent, orally available pan-RAF inhibitor with antitumor activity that acts by inhibiting downstream MAPK pathway signaling. It is used in cancer research.

  • Sorafenib-d3

    Sorafenib-d3 is a deuterium-labeled Sorafenib which is a multikinase inhibitor(IC50s: 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively).

  • RMC-0331

    RMC-0331 (RM-023) is an orally available and potent SOS1 inhibitor with potential anticancer activity, blocking RAS activation by disrupting RAS-SOS1 interactions.